LAG3 and neoplasm: Responders to ICIs demonstrated significantly higher proportions of LAG-3+ cells compared with non-responders (p = 0.0210), and patients with ≥1% LAG-3+ tumor cells had significantly longer PFS than those with <1% LAG-3 (p = 0.0037) [64].